Nimbex (Cisatracurium)

Cisatracurium competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from triggering depolarization and muscle contraction. This inhibition produces a dose‑dependent relaxation of skeletal muscles, allowing clinicians to control ventilation and surgical conditions.

The dose of Nimbex is individualized by the prescribing clinician based on the patient’s weight, clinical condition, and desired depth of neuromuscular blockade. Typical regimens involve an initial bolus followed by a maintenance infusion, but exact amounts are determined at the bedside.

Cisatracurium is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no adequate human studies. It should be used only when the potential benefit justifies any potential risk to the fetus, and breastfeeding decisions should follow clinical judgment.

To order Nimbex, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Compared with agents such as rocuronium or vecuronium, cisatracurium (Nimbex) is eliminated primarily by Hofmann degradation rather than hepatic or renal pathways, reducing the risk of accumulation in organ‑impaired patients. Its onset is slightly slower than some alternatives, but it offers predictable recovery and a favorable safety profile in diverse clinical settings.

Nimbex should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should be kept in its original packaging until use, and any unused solution should be discarded according to local regulations.

Nimbex is supplied as an injectable solution for intravenous administration. It is typically given as an initial bolus to achieve rapid paralysis, followed by a continuous infusion to maintain the desired level of neuromuscular blockade during surgery or mechanical ventilation.

Serious risks include anaphylactic reactions, prolonged or unexpected neuromuscular blockade, severe hypotension or cardiovascular collapse, and respiratory depression if the drug’s effect is not adequately reversed. Continuous monitoring of neuromuscular function and hemodynamics is essential to detect these events promptly.

Nimbex is contraindicated in patients with a known hypersensitivity to cisatracurium or any of its excipients. Caution is also advised in individuals with severe hepatic or renal impairment, and in pregnant or lactating women unless the therapeutic benefit outweighs potential risks.